Patrick Ma, M.D., co-leader of the WVU Cancer Institute Sara Crile Allen & James Frederick Allen Comprehensive Lung Cancer Program and director of the Clinical Lung Cancer Program, and Xiaoliang Wu, M.D., Ph.D., postdoctoral research fellow in Dr. Ma’s lab, were featured presenters at the 2018 American Society of Clinical Oncology (ASCO) Annual Scientific Meeting this June.
In addition to serving in several leadership roles at the ASCO meeting, including member of the Educational Committee, tumor biology track leader of the Scientific Program Committee and session chair for the Tumor Biology Oral Abstract Session and an Education Session, Dr. Ma presented two talks – Linking Immune and Genomic Heterogeneity: Clinical and Biologic Implications and Novel Platforms and Clinical Applications for Noninvasive Molecular Testing. Both focused on topics at the forefront of modern cancer research – genomic profiling and immune repertoire profiling, and novel molecular diagnostic platforms, such as liquid biopsy and breath biopsy. His research titled PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance was also selected to be highlighted in a Poster Discussion Session during the meeting.
Dr. Wu won a 2018 Conquer Cancer Foundation of ASCO Merit Award based on his research presentation Mass spectrometry biomolecular omics profiling and imaging to dissect the initial emergence of molecular drug resistance in ALK-positive (ALK+) lung cancer, which was featured during a Poster Discussion Session. Using cutting-edge technology, he was able to pinpoint when drug resistance began at a molecular level in lung cancer cells that received precision therapy. His work identified tumor cell protein reprogramming as early as 7 days while the majority of tumor cells were being killed off by the precision therapy.
Dr. Wu also presented Whole exome sequencing (WES) to define the genomic landscape of young lung cancer patients during an Oral Abstract Session. In that research project he leveraged state-of-the-art, next-generation cancer genome sequencing technology to unravel the genomic mystery of why lung cancer occurs in young patients, under 45 years of age, often without any smoking history.
ASCO’s Annual Meeting brought together more than 40,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
W est Virginia University’s Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator. A native of upstate New York, the renowned gastrointestinal cancer expert came to Morgantown about two years ago. Goldberg previously worked at The Ohio State University’s Wexner Medical Center, where he served as the Klotz Family Professor of Cancer Research, the physician‐in‐ chief of the James Cancer Hospital, the associate director of the Ohio State Comprehensive Cancer Center and the acting division director of the Division of Medical Oncology. Before that, he also worked at the University of North Carolina and the Mayo Clinic. Goldberg is one of many world-class physicians recruited by WVU Medicine during the past few years, whose research has resulted in more than 300 peer-reviewed publications, including those in the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology
The WVU Cancer Institute is among six organizations to receive an inaugural Medline Breast Cancer Awareness grant, which is awarded to organizations to further the mission to eradicate breast cancer and provide counseling. The grant drives awareness around prevention and early detection by providing support to organizations that provide direct patient care.
Researchers across campus are taking a One WVU approach to solving important problems and saving lives. At its core, an experimental therapeutics platform that integrates multiple disciplines from chemistry and biology to the health sciences and cancer institute.